Effect of cholinergic precursor choline alfoscerate on cognitive and behavioral symptoms in patients with mild cognitive impairment (mild cognitive impairment) [Effetto del precursore colinergico colina alfoscerato sui sintomi cognitivi e comportamentali in pazienti affetti da danno cognitivo lieve (mild cognitive impairment) Effetto del precursore colinergico colina alfoscerato sui sintomi cognitivi e comportamentali in pazienti affetti da danno cognitivo lieve (mild cognitive impairment)]

Trial Profile

Effect of cholinergic precursor choline alfoscerate on cognitive and behavioral symptoms in patients with mild cognitive impairment (mild cognitive impairment) [Effetto del precursore colinergico colina alfoscerato sui sintomi cognitivi e comportamentali in pazienti affetti da danno cognitivo lieve (mild cognitive impairment) Effetto del precursore colinergico colina alfoscerato sui sintomi cognitivi e comportamentali in pazienti affetti da danno cognitivo lieve (mild cognitive impairment)]

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2014

At a glance

  • Drugs Choline alfoscerate (Primary)
  • Indications Cognition disorders
  • Focus Therapeutic Use
  • Sponsors MDM SpA
  • Most Recent Events

    • 28 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top